DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.
Key Details
- 1FDA cleared DeepHealth's Prostate Suite, an AI platform for prostate MRI workflows.
- 2Tool provides AI assistance for lesion detection, risk assessment, segmentation, and PI-RADS reporting.
- 3Compatible with 11 fusion biopsy systems, integrating with radiologists' existing tools.
- 4Real-world use: detected 27% more lesions, reduced segmentation variability by 65%, and cut biopsy workflow times by 37%.
- 5RadNet also received CE Mark in Europe for Brain Health, Brain Age, and LumbarMR AI solutions.
- 6LumbarMR AI supports lumbar spine MRI analysis, added through Gleamer acquisition.
Why It Matters
FDA clearance signals increasing acceptance and integration of AI tools in radiology. These solutions may meaningfully improve cancer detection accuracy, workflow efficiency, and broader access to prostate and other disease screenings.
Source
Radiology Business
Related News
•Radiology Business
Real-World Study: Radiology AI Best in Emergency and Inpatient Settings
A commercial AI tool for intracranial aneurysm detection outperformed in inpatient and emergency settings but yielded limited benefits for outpatients in a major health system study.
•Radiology Business
AI Model Surpasses Radiologists in Detecting Subtle Hip Fractures
A new AI model outperformed radiologists in identifying difficult-to-detect femoral neck fractures on radiographs.
•AuntMinnie
AI-Driven Whole-Body MRI Biomarkers Aid Myeloma Risk Stratification
AI-powered MRI analysis offers automated risk stratification via body composition in multiple myeloma patients.